<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03613246</url>
  </required_header>
  <id_info>
    <org_study_id>NVT04FOL</org_study_id>
    <nct_id>NCT03613246</nct_id>
  </id_info>
  <brief_title>NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population</brief_title>
  <acronym>FOLLOW</acronym>
  <official_title>Clinical Outcomes of the NVT ALLEGRA TAVI System TF in Failing Calcified Aortic Heart Valves in a Real-world Patient Population With Elevated Surgical Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NVT GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NVT GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study collects real-world data of patients who were treated with the ALLEGRA TAVI System&#xD;
      TF and evaluates early and midterm clinical and quality of life outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>30 days post-index procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success of implantation</measure>
    <time_frame>day of procedure</time_frame>
    <description>Technical success of implantation, as defined by:&#xD;
absence of procedural mortality AND&#xD;
correct positioning of a single prosthetic heart valve into the proper anatomical location AND&#xD;
no prosthesis - patient mismatch AND&#xD;
mean aortic valve gradient &lt;20 mmHg, AND&#xD;
no moderate or severe prosthetic valve regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment of NYHA classification</measure>
    <time_frame>30 days, 12 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile according to VARC II</measure>
    <time_frame>30 days</time_frame>
    <description>Early Safety&#xD;
All-cause mortality&#xD;
All stroke (disabling and non-disabling)&#xD;
Life-threatening bleeding&#xD;
Acute kidney injury-Stage 2 or 3 (including renal replacement therapy)&#xD;
Coronary artery obstruction requiring intervention&#xD;
Major vascular complication&#xD;
Valve-related dysfunction requiring repeat procedure&#xD;
Time-related valve safety&#xD;
Structural valve deterioration as defined by&#xD;
Requiring repeat procedure (transcatheter or surgical heart valve replacement)&#xD;
Valve-related dysfunction defined by&#xD;
mean aortic valve gradient ≥20 mmHg and&#xD;
no moderate or severe prosthetic valve regurgitation&#xD;
Prosthetic valve endocarditis&#xD;
Prosthetic valve thrombosis&#xD;
Thrombo-embolic events (e.g. stroke)&#xD;
VARC bleeding, unless clearly unrelated to valve therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>date of procedure till date of estimated discharge, assessed up to two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (EQ5D 5L)</measure>
    <time_frame>30 days, 12 month, 24 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New pacemaker implantation</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assessment of mean aortic gradient post-implantation</measure>
    <time_frame>up to two years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Transcatheter Aortic Valve Implantation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic patients with elevated surgical risk and candidate for TAVI with severe&#xD;
        calcified and stenotic aortic valves or failing surgical bioprosthetic aortic valves.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Symptomatic degeneration of severe calcified aortic heart valve OR failing surgical&#xD;
             aortic bioprosthetic valve&#xD;
&#xD;
          2. Acceptable candidate for elective treatment with the ALLEGRA TAVI System TF (according&#xD;
             to the most recent version of the ALLEGRA Instructions For Use)&#xD;
&#xD;
          3. High risk for surgery as assessed by the heart team&#xD;
&#xD;
          4. Has signed the Patient Informed Consent Form &gt;= 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          1. Echocardiographic evidence of intracardiac thrombus or vegetation&#xD;
&#xD;
          2. Significant aortic disease such as severe obstructive calcification or marked&#xD;
             tortuosity or kinking which will preclude a safe advancement of the ALLEGRA TAVI&#xD;
             System TF&#xD;
&#xD;
          3. Iliofemoral vessel conditions such as severe obstructive calcification, severe&#xD;
             tortuosity or kinking that would preclude safe placement of an 18 Fr introducer sheath&#xD;
             or make endovascular access to the aortic valve impossible&#xD;
&#xD;
          4. Severe ventricular dysfunction with LVEF &lt;20%&#xD;
&#xD;
          5. Evidence of active endocarditis or other acute infections&#xD;
&#xD;
          6. Renal failure requiring continuous renal replacement therapy&#xD;
&#xD;
          7. Known hypersensitivity to contrast media, which cannot be adequately pre-medicated or&#xD;
             contraindication to anticoagulant or anti-platelet medication or to nitinol alloy or&#xD;
             to bovine tissue&#xD;
&#xD;
          8. Life expectancy ≤ 12 months due to other medical illness&#xD;
&#xD;
          9. Currently participating in another investigational drug or device study&#xD;
&#xD;
        Patients with native aortic valve disease:&#xD;
&#xD;
          1. Unicuspid or bicuspid aortic valve&#xD;
&#xD;
          2. Non-calcified aortic stenosis&#xD;
&#xD;
          3. Combined aortic valve disease with predominant aortic regurgitation &gt; 3&#xD;
&#xD;
          4. Distance between aortic valve basal plane and the orifice of the lowest coronary&#xD;
             artery &lt; 8 mm&#xD;
&#xD;
        Patients with degenerated surgical bioprosthetic aortic valves:&#xD;
&#xD;
          1. Low position of the coronary ostia, especially in combination with shallow sinuses&#xD;
&#xD;
          2. Internal diameter of the bioprosthesis is ≤16 mm or &gt;28 mm&#xD;
&#xD;
          3. Partially detached leaflets that in the aortic position may obstruct a coronary ostium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Schäfer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kath. Marienkrankenhaus Hamburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Faiss, PhD</last_name>
    <phone>+49 7471 98979</phone>
    <phone_ext>230</phone_ext>
    <email>martin.faiss@nvt-med.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jarkko Piuhola, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefäßzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Burgdorf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kath. Marienkrankenhaus</name>
      <address>
        <city>Hamburg</city>
        <zip>22087</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Schäfer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MH Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Widder, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Montorfano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heartcentre Catharina Hospital Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pim Tonino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Moreno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <zip>36213</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Iñiguez, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TAVI</keyword>
  <keyword>Aortic valve stenosis</keyword>
  <keyword>ALLEGRA</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

